EUVIMEDEUVIMED entdecken
Crossref

Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials

Bellinda L King-Kallimanis, Melanie Calvert, David Cella, Kim Cocks, Corneel Coens, Diane Fairclough, Lynn Howie, Pall Jonsson, Nirosha Mahendraratnam, Julia Maues, Sinan Sarac, Jim Shaw und 3 weitere

Value in Health · 2023

DOI: 10.1016/j.jval.2023.06.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2023. Verfasst von Bellinda L King-Kallimanis und 14 weiteren Autor:innen. Beteiligte Einrichtung: LUNGevity Foundation, Bethesda, MD, USA. Electronic address: bking-kallimanis@lungevity.org. Hauptthemen laut MEDLINE: Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Patient-reported outcome (PRO) data are critical in understanding treatments from the patient perspective in cancer clinical trials. The potential benefits and methodological approaches to the collection of PRO data after treatment discontinuation (eg, because of progressive disease or unacceptable drug toxicity) are less clear. The purpose of this article is to describe the Food and Drug Administration's Oncology Center of Excellence and the Critical Path Institute cosponsored 2-hour virtual roundtable, held in 2020, to discuss this specific issue. METHODS: We summarize key points from this discussion with 16 stakeholders representing academia, clinical practice, patients, international regulatory agencies, health technology assessment bodies/payers, industry, and PRO instrument development. RESULTS: Stakeholders recognized that any PRO data collection after treatment discontinuation should have clearly defined objectives to ensure that data can be analyzed and reported. CONCLUSIONS: Data collection after discontinuation without a justification for its use wastes patients' time and effort and is unethical.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsDrug-Related Side Effects and Adverse ReactionsHumansMedical OncologyData CollectionPatient Reported Outcome Measures

Stichwörter der Autor:innen

clinical trialsmultistakeholder perspectiveoncologypatient-reported outcomes

Autor:innen und Institutionen

  • LUNGevity Foundation, Bethesda, MD, USA. Electronic address: bking-kallimanis@lungevity.org.
  • Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, England, UK; Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, College of…
  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
  • Adelphi Values, Cheshire, England, UK.
  • Quality of Life Department, EORTC HQ, Brussels, Belgium.
  • Colorado School of Public Health, Aurora, CO, USA.

Zitieren

APA

King-Kallimanis, B. L., Calvert, M., Cella, D., Cocks, K., Coens, C., Fairclough, D., Howie, L., Jonsson, P., Mahendraratnam, N., Maues, J., Sarac, S., Shaw, J., Stigger, N., Trask, P., & Wieseler, B. (2023). Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials. Value in Health. https://doi.org/10.1016/j.jval.2023.06.019

Vancouver

King-Kallimanis BL, Calvert M, Cella D, Cocks K, Coens C, Fairclough D, et al. Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials. Value in Health. 2023. doi:10.1016/j.jval.2023.06.019

BibTeX
@article{KingKallimanis2023,
  author = {King-Kallimanis, Bellinda L and Calvert, Melanie and Cella, David and Cocks, Kim and Coens, Corneel and Fairclough, Diane and Howie, Lynn and Jonsson, Pall and Mahendraratnam, Nirosha and Maues, Julia and Sarac, Sinan and Shaw, Jim and Stigger, Nichelle and Trask, Peter and Wieseler, Beate},
  title = {Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials},
  journal = {Value in Health},
  year = {2023},
  doi = {10.1016/j.jval.2023.06.019}
}
Kostenlos starten →